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Abstract
Background: Aging is often associated with behavioral impairments, but some people age more gracefully than
others. Why? One factor that may play a role is individual differences in the distinctiveness of neural
representations. Previous research has found that neural activation patterns in visual cortex in response to different
visual stimuli are often more similar (i.e., less distinctive) in older vs. young participants, a phenomenon referred to
as age-related neural dedifferentiation. Furthermore, older people whose neural representations are less distinctive
tend to perform worse on a wide range of behavioral tasks. The Michigan Neural Distinctiveness (MiND) project
aims to investigate the scope of neural dedifferentiation (e.g., does it also occur in auditory, motor, and
somatosensory cortex?), one potential cause (age-related reductions in the inhibitory neurotransmitter gamma-
aminobutyric acid (GABA)), and the behavioral consequences of neural dedifferentiation. This protocol paper
describes the study rationale and methods being used in complete detail, but not the results (data collection is
currently underway).
Methods: The MiND project consists of two studies: the main study and a drug study. In the main study, we are
recruiting 60 young and 100 older adults to perform behavioral tasks that measure sensory and cognitive function.
They also participate in functional MRI (fMRI), MR spectroscopy, and diffusion weighted imaging sessions, providing
data on neural distinctiveness and GABA concentrations. In the drug study, we are recruiting 25 young and 25
older adults to compare neural distinctiveness, measured with fMRI, after participants take a placebo or a
benzodiazepine (lorazepam) that should increase GABA activity.
Discussion: By collecting multimodal imaging measures along with extensive behavioral measures from the same
subjects, we are linking individual differences in neurochemistry, neural representation, and behavioral performance,
rather than focusing solely on group differences between young and old participants. Our findings have the
potential to inform new interventions for age-related declines.
Trial registration: This study was retrospectively registered with the ISRCTN registry on March 4, 2019. The
registration number is ISRCTN17266136.
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Background
Normal aging is associated with pervasive declines in cogni-
tive, motor, and sensory function, even in the absence of
significant disease. Further, both the number of older adults
and the proportion of older adults in the population are
growing at alarming rates. Consequently, tens of millions of
healthy people are already experiencing age-related behav-
ioral impairments, and that number is only going to grow.
Nevertheless, there are substantial individual differences in
age-related behavioral impairments. Some otherwise
healthy people experience significant age-related declines,
while others do not. What distinguishes those who age
gracefully from those who experience significant impair-
ments? The answer to that question could transform efforts
to reduce, or even reverse, behavioral impairments associ-
ated with aging.
One factor that may play an important role in explain-
ing individual differences in aging is neural distinctiveness.
Neural distinctiveness refers to the extent to which neural
activation patterns evoked by different stimuli are distin-
guishable [1]. If two stimuli elicit activation in relatively
disjoint neural populations, then the representations of
those stimuli are quite distinct. Conversely, if the activated
populations overlap substantially, then the representations
are not very distinct. Functional neuroimaging data sug-
gest that neural activation patterns in response to different
stimuli are significantly less distinct in older compared
with younger adults, a phenomenon referred to as
age-related neural dedifferentiation [2–4]. Furthermore,
older adults who exhibit preserved neural distinctiveness
have been found to perform better than other older adults
on a range of fluid processing tasks [4].
Most of the previous evidence for neural dedifferenti-
ation has been found in the visual cortex during visual
tasks. An important open question is the extent to which
dedifferentiation extends to other brain regions and tasks.
Single-neuron recording studies suggest that somatosen-
sory [5, 6] and auditory representations [7] become less
distinct in senescent animals. While evidence in humans
remains sparse, recent studies hint that age-related neural
dedifferentiation occurs outside of the visual cortex and
during non-visual tasks in humans as well. Payer and col-
leagues [8] reported age-related declines in neural distinct-
iveness in the ventral visual cortex as well as the
prefrontal cortex during memory encoding. Neural dedif-
ferentiation has also been observed in the inferior parietal
cortex and in the medial and lateral prefrontal cortex
using a whole-brain multivariate searchlight analysis [2].
Reduced distinctiveness has also been reported in the
motor activity evoked by left vs. right hand tapping in
older vs. younger subjects [9].
These findings suggest that age-related neural dediffer-
entiation may indeed be a general feature of the aging
brain. The first aim of our main study is to test that
hypothesis. Specifically, we are testing whether neural
representations are less distinct in old than in young
adults in a variety of task domains (vision, hearing,
touch, motor control) and brain regions (visual cortex,
auditory cortex, somatosensory cortex, motor cortex).
We will also evaluate cross-domain relationships in
neural distinctiveness: do older adults with less distinct
visual representations also exhibit less distinct motor,
somatosensory, and auditory representations? This issue
has important implications for theoretical models of
cognitive aging. Common-cause theories argue that
age-related declines occur in tandem across domains,
but process-specific theories predict that different abil-
ities decline independently [10].
Previous work has demonstrated that neural representa-
tions become less distinctive in old age, but what causes
this neural dedifferentiation? Evidence from work in
non-human primates suggests that age-related reductions
in the inhibitory neurotransmitter gamma-aminobutyric
acid (GABA) may play a role. Leventhal and colleagues [1]
demonstrated a relationship between GABA activity and
neural selectivity in the visual cortex of old and young ma-
caques. At baseline, visual neurons in older macaques
responded non-selectively to orientation, showing strong
responses to stimuli at a variety of different orientations.
However, just minutes after the electrophoretic applica-
tion of either GABA or the GABA agonist muscimol,
these same cells showed strong selectivity for stimulus
orientation. These effects disappeared over time, or imme-
diately with the application of the GABA antagonist bicu-
culline. Conversely, visual neurons in young macaques
were strongly orientation-selective at baseline, and they
remained so after application of GABA. However, the ap-
plication of the GABA antagonist bicuculline abolished
visual selectivity in these cells and made them look like
the neurons of old macaques at baseline.
Given these findings, our second aim is to investigate
the relationship between GABA and neural distinctive-
ness in humans. In our main study, we are using mag-
netic resonance spectroscopy (MRS) to measure
individual differences in GABA concentrations. We pre-
dict that GABA levels will be lower in older participants
compared with younger participants and that partici-
pants with higher levels of GABA in specific cortical re-
gions will exhibit greater neural distinctiveness in those
same regions. In a linked drug study, we are manipulat-
ing GABA activity pharmacologically in a subset of par-
ticipants to assess the impact of this manipulation on
neural distinctiveness. We predict that increasing GABA
activity via a low oral dose of a benzodiazepine (loraze-
pam, 0.5 mg) will lead to increased neural distinctiveness
within individual subjects.
The third aim is to test whether individual differences
in neural distinctiveness predict individual differences in
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behavior, particularly in older participants. Park et al. [4]
found that individual differences in neural distinctive-
ness in the visual cortex predicted performance on a
range of fluid processing tasks in older adults. In fact,
neural distinctiveness accounted for 30% of the variance
in behavioral performance, despite the fact that neural
distinctiveness was only measured in visual cortex using
simple visual tasks while the fluid processing tasks re-
quired far more general types of cognitive processing. In
order to investigate the behavioral consequences of
neural distinctiveness more thoroughly, we propose to
collect a full battery of cognitive and sensorimotor mea-
sures in all of the participants in the main study.
Methods
Main study
The goal of the main study is to evaluate the scope of
neural dedifferentiation, whether age-related declines in
GABA may be a cause, and its behavioral consequences.
Participants
All participants are healthy, right-handed, native English
speakers. Participants are aged 18–29 years (young
adults) or 65 years and older (older adults). Inclusion
and exclusion criteria are listed in Table 1. All sessions
take place at the University of Michigan’s Functional
MRI Laboratory at the Bonisteel Interdisciplinary Re-
search Building and the Ann and Robert H. Lurie Bio-
medical Engineering Building in Ann Arbor, Michigan.
Participants are being recruited from the Ann Arbor
community and the surrounding area. We have two
main systems of recruitment. We post flyers throughout
the community (libraries, university and college cam-
puses, community centers, local stores, etc.) advertising
the study details. The University of Michigan also hosts
a website (https://umhealthresearch.org/) where individ-
uals can learn about studies being conducted through
the university and contact researchers if they are inter-
ested in participating.
Power calculations
Park et al. [4] reported correlations between neural dis-
tinctiveness and fluid intelligence among older adults
ranging from r = 0.275 to r = 0.59. To achieve 80% power
to detect a correlation of r = 0.275, approximately 100
older subjects would be required. Thus, we are targeting
a sample of 100 older adults. Carp, Park, Polk, et al. [2]
found that the neural representations of visual stimuli
are less distinct in older adults than in young adults
(Cohen’s d = 1.06). To achieve 80% power to detect an
effect of this size, a sample of approximately 15 subjects
per group would be required. We are targeting 60 young
adults (in addition to our 100 older adults) which will
provide more than enough power to examine differences
between the two age groups.
Session design
After completing an initial telephone screening interview
and being determined eligible, all subjects participate in
three separate sessions. Session 1 lasts two hours and
consists only of cognitive and behavioral tasks. Session 2
includes 45 min of behavioral testing and an hour-long
functional magnetic resonance imaging (fMRI) scan. Ses-
sion 3 includes a 1.5-h MRS scan. The tasks in the fMRI
scan are counterbalanced across participants. See Table 2
for an overview of the study flow. Blinding procedures
are not necessary for the main study because there is no
between-subject or between-session manipulation of
interest. Participants provide verbal consent during the
screening interview and written consent at the beginning
of Session 1.
Cognitive and behavioral tasks
Several tasks are being administered to assess sensory
and cognitive abilities. The tasks are described below
and are grouped by domain. All tasks referencing the
NIH Toolbox are administered on an iPad using the
NIH Toolbox® for Assessment of Neurological and Be-
havioral Function iPad App [11]. Detailed information
about the NIH Toolbox scoring methodology can be
Table 1 Main study exclusion and inclusion criteria
Exclusion Criteria Inclusion Criteria
• Hearing problems or use of a hearing aid
• Color blindness
• Motor control problems
• Psychotropic medication
• Current depression or anxiety, or occurrence of depression/anxiety within 5 years
• Concussion with unconsciousness for 5 min or more
• Pregnancy or attempting to become pregnant
• More than 4 alcoholic drinks per week for women, more than 6 for men
• History of drug or alcohol abuse or addiction
• Weight greater than 250 pounds
• MRI incompatibility (claustrophobic, foreign metallic objects, pacemaker, etc.)
• Age 18–29 years or 65 years and older
• Right-handed
• Native English speaker
• Healthy (i.e., no debilitating conditions, mental illness, or head trauma)
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found in the scoring guide located on the NIH Toolbox
website [12]. Participants complete these tasks during
Sessions 1 and 2. Table 3 shows the task administration
order. Participants also completed the Cognitive Failures
Questionnaire during the screening process [13, 14].
Visual function
1. NIH Toolbox Visual Acuity Test
This test measures binocular distance visual
acuity. Letters appear one at a time on an iPad
screen at eye level and participants view them
from a distance of 3 m. Participants verbally state
the letter they see on the screen, and responses
are recorded by the researcher using an iPad
wireless keyboard. The letters get smaller
following a correct response, and they get larger
following an incorrect response. Participants are
instructed to wear corrective contact lenses or
glasses, if any. The software automatically
calculates a LogMAR score (a modified version
of a Snellen visual acuity score) and converts it
to a standard score.
2. Visual Tasks in Noise
Four visual tasks in noise are administered on a
Dell laptop with a 15.6-in. screen using the
Psychophysics Toolbox [15, 16] in MATLAB [17].
The details of the four tasks are described below,
but all of them consist of a fixation cross presented
for 500 ms followed by a black and white picture
presented in dynamic Gaussian noise for 500 ms.
After the picture is presented, a response screen
appears. After participants make their response, the
next trial begins. The order of the stimulus
presentation is pseudorandomized and is the same
for each participant. Each task has 4 practice trials
with feedback provided and 50 scored trials without
feedback. The tasks follow a staircase procedure.
When a participant makes three correct responses
in a row, the next trial increases by one level of
noise. Following an incorrect response, the amount
of noise is decreased by one level. There are 15
levels of Gaussian noise, and each task starts at
the 5th level of noise. The dependent measure is
the average level of noise presented for the last
40 trials.
a. Buildings in Noise (BIN)
The stimulus picture is either a house (50% of
trials) or an apartment (50% of trials).
Participants are asked to press “1” on the
keyboard with their left index finger if they
think the picture was a house and to press “0”
with their right index finger if they think the
picture was an apartment building. Building
images are gathered from the same stimulus set
used in Park et al. [3].
b. Faces in Noise (FIN)
The stimulus picture is either a male (50% of
trials) or female (50% of trials) face. Participants
are asked to press “1” on the keyboard with
their left index finger if they think the picture
was a male face and to press “0” with their right
index finger if they think the picture was a
female face. Face stimuli are from Gold,
Bennett, and Sekuler [18].
c. Objects in Noise (OIN)
The stimulus picture is either an office item,
such as a stapler or writing utensil (50% of
trials), or a food item, such as a hamburger or
salad (50% of trials). Participants are asked to
press “1” on the keyboard with their left index
finger if they think the picture was an office
item and to press “0” with their right index
finger if they think the picture was a food item.
Object stimuli are from Brady, Konkle, Alvarez,
and Oliva [19].
d. Scenes in Noise (ScIN)
The stimulus picture is either an urban (50% of
trials) or nature (50% of trial) scene. Participants
are asked to press “1” on the keyboard with
Table 2 Overview of experimental flow for the main study.
Specific assessment titles are further outlined in Table 3
Main Study
Timepoint: Enrolment Session
1
Session
2
Session
3
Enrolment:
Eligibility screen X
Informed consent X X
Condition Allocation X
Assessments:
Cognitive Impairment
Screen
X
Fluid Intelligence Measures X X
Crystallized Intelligence
Measures
X
Visual Function X X
Auditory Function X
Tactile Function X
Motor Function X X
MRI:
fMRI Sensory Tasks X
fMRI Resting State X
DWI X
MRS X
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their left index finger if they think the picture
was an urban scene and to press “0” with their
right index finger if they think the picture was a
nature scene. Scene images are from Zhou,
Lapedriza, Khosla, Oliva, and Torralba [20].
Auditory function
1. NIH Toolbox Words-In-Noise Test (WIN)
Measures how well participants hear words in a
noisy environment. While wearing over-the-ear
Table 3 Main study behavioral tasks and fMRI session sequence
Session Measure Domain Approx. Time (min)
1 – Behavior Only MoCA Cognitive Screening Tool 10
VPA_1 Episodic Memory 9
Faces in Noise Visual 2
Auditory Threshold Auditory Screening Tool 7
Sentences in Noise Auditory 7
Objects in Noise Visual 2
Symbol Search Processing Speed 4
VPA_2 Episodic Memory 3
Coding Processing Speed 3
Buildings in Noise Visual 2
Purdue Pegboard 1 Motor 5
Digits in Noise Auditory 4
Purdue Pegboard 2 Motor 3
Scenes in Noise Visual 2
Break 5
NIH Words-In-Noise Test Auditory 6
NIH Flanker Inhibitory Control and Attention Test Executive Function 3
NIH List Sorting Working Memory Test Working Memory 9
NIH Dimensional Change Card Sort Test Executive Function 5
NIH Pattern Comparison Processing Speed Test Processing Speed 3
NIH Picture Sequence Memory Test Episodic Memory 6
NIH Picture Vocabulary Test Crystallized Intelligence 3
NIH Oral Reading Recognition Test Crystallized Intelligence 3
NIH 9-Hole Pegboard Dexterity Test Motor 6
NIH Grip Strength Test Motor 3
2 – Behavior + fMRI RBMT Story 1 Episodic Memory 2
Static Detection Threshold
Right Hand
Tactile 3
Dynamic Threshold
Right Hand
Tactile 3
Dynamic Threshold
Intra-hemispheric Conditioning
Tactile 5
Dynamic Threshold
Inter-hemispheric Conditioning
Tactile 5
NIH Visual Acuity Test Visual 2
RBMT Story 2 Episodic Memory 2
Functional Tactile Object Recognition Tactile 5
NIH 2-Minute Walk Endurance Test Motor 6
fMRI Task Preview 10
fMRI 50
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noise cancelling headphones, participants hear sin-
gle words presented with varying levels of back-
ground noise. Words are presented separately to
the right and left ears. Participants are instructed to
say the word they thought they heard. The exam-
iner indicates a correct or incorrect response on the
iPad. The software automatically generates a raw
score, hearing threshold, and standard score for
each ear.
2. Digits in Noise
This task was developed by the Nottingham
University Hospitals NHS Trust and resembles the
Digit Triplet Test [21]. Participants are asked to
discern numbers presented in background noise.
The task is administered on a Dell laptop using
MATLAB [17]. Groups of 3 numbers are presented
binaurally with varying signal-to-noise ratios (SNR).
The level of noise is kept constant, while the decibel
(dB) level of the digits varies. All participants start
at 14 dB SNR. Following a correct response, the
next trial is presented with the SNR decreased by 2
dB. Following an incorrect response, the next trial
is presented with the SNR increased by 2 dB. Partic-
ipants complete 24 trials, and their speech reception
threshold is calculated by averaging the SNR dB of
the last 19 trials. The task is presented using over-
the-ear noise cancelling headphones, and partici-
pants adjust the volume to a comfortable level be-
fore beginning the task.
3. Sentences in Noise
This task assesses how well participants can hear
sentences presented in noise. The task is
administered on a Dell laptop using the Oscilla
USB-350SP PC-based audiometer software with
TDH-39 headphones. Sentences are presented mon-
aurally, and the volume is set to a comfortable level
for each ear before starting the task. Three lists,
each consisting of six sentences, are presented to
each ear. After a sentence is presented, the partici-
pant is instructed to repeat back what they heard,
and the researcher indicates their response on the
laptop. The software automatically generates the de-
gree of SNR loss in decibels based on the number
of words the participant hears.
4. Hearing Threshold
This task is administered on a Dell laptop using the
Oscilla USB-350SP PC-based audiometer software
with TDH-39 headphones. Hearing threshold is de-
termined using the Hughson Westlake Automatic
Hearing Test. Tones are presented monaurally at
125, 250, 500, 1000, 2000, 4000, and 8000 Hz. Par-
ticipants are instructed to press a response button
when they can hear a tone. The test begins by pre-
senting a tone at 20 dB. The hearing level increases
by 5 dB until the participant responds. Participants
must respond to 2 out of 3 presentations of the
same hearing level at each frequency before moving
on to the next frequency. The minimum decibel
level at which the participant responded to at least
2 out 3 presentations is recorded. The pure tone
average (PTA) is calculated for each ear using the
recorded decibel levels at 500, 1000, and 2000 Hz.
Tactile function
1. Brain Gauge Vibrotactile Tasks
A pair of piezoelectric vibrotactile stimulators
(CM5, Cortical Metrics, LLC) are used to measure
tactile function using the four tasks described below
[22]. In all four tasks, vibrations are delivered to the
pads of the index and middle fingers of the left and
right hands via plastic probes measuring 5 mm in
diameter. The tasks are controlled by a Windows
Dell laptop using the Brain Gauge software
application (Cortical Metrics, LLC). Participants use
a standard computer mouse to respond to the
stimuli.
a. Static Detection Threshold [23]
A single vibrotactile stimulation is delivered to the
right index or the right middle finger at a frequency
of 25 Hz. The participant indicates which of the
two fingers they felt the vibration on by using the
mouse with their left hand to click a button on the
monitor screen. The task consists of 20 trials of
stimulation; 10 stimuli are randomly presented to
each finger for 500 ms. The task begins with a
stimulus amplitude of 15 μm, and subsequent
stimuli amplitudes are determined using a staircase
procedure. For the first half of the trials, if the
participant responds correctly the amplitude
decreases by 1 μm; if they respond incorrectly it
increases by 1 μm. For the last half of the trials, the
amplitude decreases by 1 μm following two correct
responses and increases by 1 μm following one
incorrect response.
b. Dynamic Threshold [23]
Tactile stimulation is delivered to either the right
index or right middle finger at a frequency of 25
Hz. Each stimulus begins at an amplitude of 0 μm
then gradually increases at a rate of 2 μm per
second. Once the participant can discern which
finger they are feeling the vibration on, they make
their response by clicking a button on the monitor
screen. Participants complete a total of 7 trials, and
each trial begins with a randomized delay period of
0, 1.5, 2, or 3 s. The stimulus amplitude at the time
of the participant’s response is recorded.
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c. Dynamic Threshold with Intra-hemispheric
Conditioning
This task consists of 16 trials in which a target
stimulus is delivered to the right index finger and a
conditioning stimulus is concurrently delivered to
the right middle finger. Similar to the dynamic
threshold task previously described, the target
stimulus has a starting amplitude of 0 μm and
increases at a rate of 2 μm per second. The
conditioning stimulus is delivered at 25 Hz with an
amplitude of 15, 50, 100, or 200 μm [23, 24]. There
are four trials at each amplitude which are
randomly presented during the task. Participants
respond by pressing a computer mouse button
attached to the inner right side of the device with
their right thumb as soon as they are able to feel
the vibration on their right index finger. The
dependent variable is the stimulus amplitude at the
time of the participant’s response.
d. Dynamic Threshold with Inter-hemispheric
Conditioning
This task is the same as the intra-hemispheric task,
the only difference being that the conditioning stimu-
lus is delivered to the left index finger instead of the
right middle finger. Participants press a mouse button
with their right thumb as soon as they are able to feel
a vibration on their right index finger.
2. Functional Tactile Object Recognition [25]
In this task, participants identify everyday objects
by the sense of touch. Participants place their hand
in a box, preventing them from seeing the object,
and the examiner places an object in their hand
(soda bottle, clothespin, etc.). Participants indicate
the object they think they are holding using a
poster that has pictures of several different objects.
Participants complete six trials. Accuracy and
response time are recorded.
Motor function
1. NIH Toolbox 9-Hole Pegboard Dexterity Test
This is a test of manual dexterity. Participants place
and remove nine pegs in a pegboard using one hand
at a time. The NIH toolbox software records the time
it takes to place and remove the pegs for each hand
and generates a standardized score for each hand.
2. NIH Toolbox Grip Strength Test
This is a measure of hand strength. Participants are
seated in a chair with their feet flat on the floor.
Participants squeeze a Jamar Plus Digital
dynamometer as hard as they can for 3 s with their
arm at a 90-degree angle. The dynamometer reports
the number of pounds of force the participant
generates with each hand. This measure is recorded
in the software and converted to a standardized
score.
3. NIH Toolbox 2-Minute Walk Endurance Test
This test measures cardiovascular endurance by
recording how far participants can walk in 2 min.
Cones are placed 25 ft apart in a hallway.
Participants are instructed to walk back and forth
around the cones as fast as they can without
running or hurting themselves for 2 min. The total
distance walked is recorded and automatically
converted to a standardized score by the software.
4. Purdue Pegboard Test
Participants complete two separate tasks using the
Purdue Pegboard to measure bimanual dexterity. In
the “Both Hands” task, participants pick up a peg
with their right hand and a peg with their left hand
at the same time. They place the pegs, at the same
time, in the first row of holes, and continue to place
pegs down the rows. Participants are instructed to
place as many pegs as they can until they are told
to stop. The number of pairs of pegs placed in 30 s
is recorded.
In the “Assembly” task, participants use both hands
to create assemblies consisting of four items.
Participants are instructed to 1) pick up a peg with
their right hand; 2) while placing the peg in the
hole with their right hand, they should pick up a
washer with their left hand; 3) while placing the
washer on the peg with their left hand, they should
pick up a collar (a small metal tube) with their right
hand; 4) while placing the collar on the peg and
over the washer with their right hand, they should
pick up a washer with their left hand; 4) while
placing the washer on top of the collar with their
left hand, completing one assembly, they should
pick up a peg with their right hand to begin the
next assembly. The number of items (pegs, collars,
and washers) placed in 1 min is recorded.
Each task is conducted twice, and the average
number of pairs and items is recorded.
Cognitive impairment screening
1. Montreal Cognitive Assessment (MoCA)
The MoCA [26] is a pen and paper-based assessment
tool used to assess mild cognitive impairment. It
takes approximately 10min to administer and con-
sists of 13 short tasks. Visuospatial ability and execu-
tive function are assessed by a trail-making task,
copying a three-dimensional cube, drawing a clock,
and a verbal abstraction task. Language ability is
assessed using an animal naming task, sentence repe-
tition, and a fluency task. Memory is evaluated using
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a 5-word delayed recall task as well as a digits-
forward and digits-backward task. Attention and con-
centration are measured using a target detection task
and a subtraction task. Orientation is evaluated by
asking the participant the date and location of the
study session. Each task has a point value associated
with it. The total number of points earned is re-
corded. The highest possible score is 30 points, and a
score of 26 or higher is considered normal.
Processing speed
1. NIH Toolbox Pattern Comparison Processing
Speed Test
Participants are instructed to discern, as fast as they
can, whether two simple side-by-side pictures pre-
sented on an iPad are the same or different. Partici-
pants press buttons on the iPad screen to indicate
their response. The raw score is the number of
items they correctly answer in 85 s. The software
automatically generates the raw score and converts
it to a standard score.
2. Wechsler Adult Intelligence Scale (WAIS-IV) –
Symbol Search Subtest [27]
Each item consists of 2 target symbols adjacent to a
line of 5 search symbols. Participants are instructed
to draw a line through a search symbol if it
matches one of the target symbols. If none of the
target symbols match the search symbols, they
draw a line through a “no” box. Participants
complete as many items as they can in 2 min. Their
raw score is determined by subtracting the number
of incorrectly answered items from the number of
correctly answered items.
3. WAIS-IV – Coding Subtest [27]
A key is presented at the top of the page. In the
key, each number (1–9) has its own symbol. Below
the key is a grid consisting of rows of numbers.
Each number has an empty space below it. The
participant is instructed to draw the symbol that
corresponds to each number. Participants complete
as many number-symbol items as they can in 2 min.
Their raw score is determined by subtracting the
number of incorrectly answered items from the
number of correctly answered items.
Executive function and working memory
1. NIH Toolbox List Sorting Working Memory Test
Pictures of different foods and animals are
presented on the iPad screen one at a time.
Participants are instructed to repeat the list of items
in size order from smallest to largest. For the NIH
scoring, in order for the participants’ response to be
marked correct they must list all of the correct
items in the correct order. Partial points are not
awarded. The software automatically generates a
raw score (the number of correct responses) and
converts it to a standard score.
In order to obtain a more sensitive measure of
working memory, we have devised a way to award
partial points for participant responses. For each
list, participants receive 1 point for each item
correctly remembered regardless of order. They
also receive 1 point if the first item is correct and 1
point if the last item is correct. Finally, each item is
considered together with the item following it, and
the participant receives 1 point if that particular
pair order occurs in their response. The raw score
is the total number of points they earn.
2. NIH Toolbox Flanker Inhibitory Control and
Attention Test
A row of arrows is presented on the iPad screen,
and participants are instructed to indicate, as
quickly as they can, the direction of the middle
arrow. In some trials, the middle arrow points in
the same direction as the arrows surrounding it
(congruent trials). In other trials, the middle arrow
points in the opposite direction (incongruent trials).
In total, there are 20 trials, 40% of which are
incongruent. The participant indicates their
response in each trial by pressing a left or right
arrow button located below the row of arrows on
the iPad screen. The software generates a raw score
based on a combination of accuracy and reaction
time, which is then converted to a standard score.
3. NIH Toolbox Dimensional Change Card Sort Test
The dimensional change card sort test measures
cognitive flexibility. Participants view a target image
in the center of the iPad screen. Below the target
image are two response images: one matches the
color of the target image and the other matches the
shape of the target image. Before the images are
presented, the word “SHAPE” or “COLOR” is
displayed on the screen. If SHAPE precedes the
images, participants are to press the response image
that matches the shape of the target image. If
COLOR precedes the images, participants are to
press the response image that matches the color of
the target image. There are 30 trials, 23% of which
are color trials. The software generates a raw score
based on a combination of accuracy and reaction
time, which is then converted to a standard score.
Episodic memory
1. NIH Toolbox Picture Sequence Memory Test
(PSMT)
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A sequence of 15 images is displayed on the iPad
screen. After the sequence finishes, the participant
is instructed to recall the sequence of pictures.
Participants move images on the screen in the
order they remember them being presented. The
participant then completes a second trial consisting
of 18 images, which includes the same 15 images as
the first trial and adds 3 new images in the middle
of the sequence. The raw score is the correct
number of adjacent pairs the participant places for
each trial, which is then converted to a standard
score by the software.
2. Wechsler Memory Scale (WMS-IV) – Verbal Paired
Associates (VPA) Subtest [28]
The examiner reads a list of 14 word pairs to the
participant. Some of the word pairs consist of related
words (e.g. sock-shoe), while other pairs do not (e.g.
laugh-stand). In the first part of the test (VPA 1), the
list of word pairs is read to the participant four times.
The word pairs are presented in a different order
each time. After each presentation of the list, the
examiner says the first word of each pair, and the par-
ticipant is instructed to verbally respond with the sec-
ond word of the pair. Participants receive feedback
for every response. If a response is incorrect, they are
reminded of the correct answer. Participants receive
a point for each item they correctly respond to. There
are 56 points possible.
The second part of the subtest (VPA 2) occurs
approximately 25 min after VPA 1. This is a
surprise memory test. In VPA 2-Recall, the exam-
iner says the first word of each pair, and the partici-
pant is instructed to respond with the second word
of the pair. Participants do not receive feedback.
Their raw score is the number of items they cor-
rectly respond to out of 14 items.
In VPA 2-Recognition, the examiner reads a list of
40 word pairs. The participant is instructed to indi-
cate if the stated word pair is one of the pairs they
were presented with earlier. Their raw score is the
number of items they correctly respond to out of
40 items.
3. Rivermead Behavioral Memory Test (RBMT) –
Story Subtest [29]
In Part 1 (immediate recall), participants are
verbally presented with a brief story consisting of 5
sentences. They are instructed to listen carefully to
the story and then tell the examiner as much of the
story they can remember. Part 2 (delayed recall) is a
surprise memory test that occurs approximately 20
min after Part 1. Here, participants are again asked
to tell the examiner as much of the story they can
remember. Their raw score is the number of “ideas”
they correctly remember out of 21 possible ideas.
Crystallized intelligence
1. NIH Toolbox Picture Vocabulary Test (PV)
This test provides a measure of general vocabulary
knowledge. The test utilizes Computer Adaptive
Testing, in which each question is dependent on the
participant’s response to the previous question.
Participants hear an audio recording of a word and
four pictures are displayed on the iPad screen. They
are instructed to select the picture that best matches
the meaning of the word they heard. The software
generates a raw score using Item Response Theory,
which is then converted to a standard score.
2. NIH Toolbox Oral Reading Recognition Test (OR)
This is a measure of reading ability. A word is
presented on the iPad screen, and the participant is
instructed to read the word out-loud. Using a pro-
nunciation guide, the examiner scores the response
as correct or incorrect. Like the PV test, this test
utilizes Computer Adaptive Testing. The software
generates a raw score using Item Response Theory,
which is then converted to a standard score.
fMRI Session Protocol
Functional MRI data is collected using a 3 T General
Electric Discovery Magnetic Resonance System with an
8-channel head coil at the University of Michigan’s
Functional MRI Laboratory. The two fMRI sessions,
each lasting approximately 45 min, include the acquisi-
tion of a structural image and task-based and resting
state functional data. The first task the participants
complete is the somatosensory task. The somatosensory
task is always presented first so that the devices deliver-
ing the stimulation can be removed after this task. The
auditory task is always presented second so that the task
preceding the resting state scan (the third scan) is the
same across all participants. The visual and motor tasks
are the last two tasks, and the order of these tasks is
counterbalanced across participants.
T2*-weighted images for all four functional tasks are
collected using a 2D Gradient Echo pulse sequence with
the following parameters: Repetition Time (TR) = 2000
ms; Echo Time (TE) = 30 ms; flip angle = 90°; Field of
View (FOV) = 220 × 220 mm; 180 volumes; 43 axial slices
with thickness = 3mm and no spacing.
The specific sequence of scans is described below.
(1) 3-Plane Localizer
The localizer is generated with a 2D Gradient
Echo pulse sequence with FOV = 320 × 320 mm
and slice thickness = 10 mm with no spacing;
acquisition time = 30 s.
(2) T1-weighted Overlay
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The overlay is generated with a 2D T1-weighted
Fluid-Attenuated Inversion Recovery (FLAIR) pulse
sequence with the following parameters: TR =
3173.1 ms; TE = 24.0 ms; Inversion Time (TI) = 896
ms; flip angle = 111°; FOV = 220 × 220 mm; 43 axial
slices with thickness = 3 mm and no spacing; acquisi-
tion time = 100 s.
(3) Somatosensory Task
The vibrotactile somatosensory task lasts 6 min and
uses two Cortical Metrics Brain Gauge Pro MRI-
compatible tactile stimulators (one for each hand),
controlled using in-house Microsoft Visual Studio
scripts. The task consists of six 20-s blocks of right
index and middle finger stimulation, six 20-s blocks
of left index and middle finger stimulation, and
twelve 10-s blocks of no stimulation. Each stimula-
tion block consists of twenty 500 ms vibrations inter-
leaved with 500 ms of no vibration to create a
pulsing sensation. Each vibration block is followed
by a no-stimulation block. The vibration blocks are
pseudorandomized, and the block order is the same
for all participants. A fixation cross is presented on
the screen for the duration of the task. Target trials
consist of the 500 ms vibration delivered to one fin-
ger instead of both fingers, and there are 6 target tri-
als during the task (3 for each hand). The
participant is instructed to press a button with their
right thumb every time a target trial occurs (a
Current Designs 2-button fiber optic response unit
is attached to the right-hand stimulator to collect re-
sponse data). A target trial occurs approximately
once every minute, and there is never more than
one target trial in a given block.
(4) Auditory Task
The auditory task lasts 6 min and consists of six 20-s
blocks of foreign speech clips, six 20-s blocks of in-
strumental music clips; and twelve 10-s blocks of no
sound. Each speech block consists of a 20-s segment
of a news reporter speaking in a foreign language.
The languages used are Creole, Macedonian,
Marathi, Persian, Ukranian, and Swahili. Only one
language is used per block, and participants are
screened to ensure they are unfamiliar with the lan-
guages used. Each music block consists of a 20-s
segment of instrumental music. Each speech and
music block is followed by a no-sound block. The
speech and music blocks are pseudorandomized, and
the block order is the same for all participants. A
fixation cross is presented on the screen for the dur-
ation of the task. Target trials consist of a beep inter-
jected into the speech or music, and there are 6
target trials presented throughout the task – 3 for
speech and 3 for music. Participants are instructed
to press a button with their right index finger every
time they hear a target trial. There is a target trial
approximately once every minute, and there is never
more than one target trial in a given block. Sound is
presented through an Avotec Conformal Headset,
and responses are collected via a Celeritas 5-button
fiber optic response unit. Heart rate is collected via a
pulse oximeter placed on the left middle finger.
(5) Resting State
T2*-weighted functional resting state data is
collected with a 2D Gradient Echo pulse sequence
with the following parameters: TR = 2000 ms; TE =
30 ms; flip angle = 90°; FOV = 220 × 220 mm; 240
volumes; 43 axial slices with thickness = 3 mm and
no spacing. The resting state acquisition time is 8
min. Participants are instructed to relax, keep their
eyes open and focus on a fixation cross presented
for the duration of the scan. Heart rate is collected
via a pulse oximeter placed on the left middle finger.
(6) Visual Task
The visual task lasts for 6 min and consists of six 20-
s blocks of images of male faces, six 20-s blocks of
images of houses, and twelve 10-s blocks of a fix-
ation cross. Each block consists of the stimulus pre-
sented for 500 ms with an interstimulus interval
(ISI) of 500 ms. Every face and house block is
followed by a fixation block. The face and house
blocks are pseudorandomized, and the block order is
the same for all participants. Target trials are images
of female faces for face blocks, and images of apart-
ment buildings for house blocks. Participants are
instructed to press a button with their right index
finger every time they see a target trial. There are 6
target trials presented throughout the task – 3 for
the face blocks and 3 for the house blocks. A target
trial is presented approximately once every minute,
and there is never more than one target trial in a
given block. Responses are collected via a Celeri-
tas 5-button fiber optic response unit. Heart rate
is collected via a pulse oximeter placed on the left
middle finger.
(7) Motor Task
The motor task lasts 6 min and consists of six 20-s
blocks of a left-pointing arrow, six 20-s blocks of a
right-pointing arrow, and twelve 10-s blocks of a fix-
ation cross. Each block consists of the stimulus pre-
sented for 500 ms with a 500 ms ISI. Every arrow
block is followed by a fixation block. The arrow
blocks are pseudorandomized, and the block order is
the same for all participants. Participants are
instructed to press a button with their right thumb
every time they see a right-pointing arrow and to
press a button with their left thumb every time they
see a left-pointing arrow. Unlike the visual, auditory
and somatosensory tasks, the motor task does not
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contain target trials, since participants are already
making active responses. Responses are collected via
a Celeritas 5-button fiber optic response unit. Heart
rate is collected via a pulse oximeter placed on the
left middle finger.
(8) High-resolution Structural Image
A high-resolution T1-weighted structural image is
collected using a 3D fast spoiled gradient echo
(SPGR) BRAVO pulse sequence with the following
parameters: TR = 12.2 ms; TE = 5.2 ms; TI = 500 ms;
flip angle = 15°; FOV = 256 × 256 mm; 156 axial slices
with thickness = 1 mm and no spacing; acquisition
time = 5min.
MRS/DWI session protocol
Magnetic resonance spectroscopy (MRS) and Diffusion
Weighted Imaging (DWI) data are collected on a different
day using the same MRI scanner and head coil as the
fMRI scanning session. This session lasts approximately
1.5 h and consists of the following sequence of scans:
(1) 3-Plane Localizer
The localizer is collected using the same parameters
as in the fMRI session.
(2) T1-weighted Structural Image
The structural image is collected using the same
parameters as in the fMRI session.
(3) Diffusion Weighted Image (DWI)
DWI data are collected using a diffusion-weighted
2D dual spin echo pulse sequence with the following
parameters: TR = 7250 ms; TE = 2.5 ms; FOV =
240 × 240 mm; 32 diffusion directions; 60 axial slices
with thickness = 2.4 mm and 0.1 mm spacing. Acqui-
sition time is approximately 10 min.
(4) Magnetic Resonance Spectroscopy
We collect GABA edited MR spectra from six
cortical voxels using a MEGA-PRESS sequence [30]
with the following parameters: TR = 1800 ms; TE =
68 ms (TE1 = 15 ms, TE2 = 53 ms); 256 transients
(128 ON interleaved with 128 OFF) of 4096 data
points; spectral width = 5 kHz; frequency selective
editing pulses (14 ms) applied at 1.9 ppm (ON) and
7.46 ppm (OFF); FOV = 240 × 240 mm; voxel size =
30 × 30 × 30 mm. Acquisition time for each voxel is
approximately 8.5 min. Voxels are placed in order to
maximize overlap with fMRI activation from the
corresponding task in the same participant in their
own native space. The placements are therefore
unique to each participant. To determine voxel
placements, we conduct a general linear model
(GLM) on each fMRI task, contrasting each condi-
tion against rest. For example, in the visual task we
compute contrast maps for house vs. fixation and
for face vs. fixation. Using these two contrast maps
and the T1 structural image, we place the ventral
visual voxels to capture the areas of the highest acti-
vation (highest beta value) in the house and face
areas for each hemisphere. For the auditory voxels
we use the contrast maps for speech versus no
sound and music versus no sound. For the sensori-
motor voxels, we place the left hemisphere voxel to
capture activations from the right hand motor task
and the right hand somatosensory task. We place
the right hemisphere voxel using the left hand
activations.
Drug study
The goal of the drug study is to explore whether GABA
plays a role in age-related neural dedifferentiation. To
do so, we manipulate GABA activity pharmacologically
using lorazepam (a benzodiazepine) and investigate the
effect on neural distinctiveness assessed with fMRI. Lor-
azepam is a positive allosteric modulator of the
GABA-A receptor, potentiating its inhibitory function.
We hypothesize that increasing GABA activity experi-
mentally will increase neural distinctiveness.
Participants
Participants in the drug study do not participate in the
main study. All participants are healthy right-handed,
native English speakers aged 18–29 (young adults) or 65
and older (older adults). In addition to the major exclu-
sion criteria listed in Table 1, participants are excluded if
they have glaucoma, breathing problems, or an allergy to
benzodiazepines. They are also excluded if they are
undergoing chemotherapy, or have an immune system
disorder, or kidney or liver disease. These additional ex-
clusions are enforced due to potential interactions with
lorazepam. See Table 4 for all exclusion and inclusion
criteria. All sessions take place at the University of
Michigan’s Functional MRI Laboratory at the Bonisteel
Interdisciplinary Research Building in Ann Arbor,
Michigan.
Participants are being recruited from the Ann Arbor
community and the surrounding area. The recruitment
method is the same as in the main study. We post flyers
throughout the community (libraries, university and col-
lege campuses, community centers, local stores, etc.) ad-
vertising the study details. The University of Michigan
also hosts a website (https://umhealthresearch.org/) where
individuals can learn about studies being conducted
through the university and contact researchers if they are
interested in participating.
Power calculations
Tso, Fang, Phan, Welsh, and Taylor [31] is one of the few
studies to investigate the effects of lorazepam on blood-
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oxygen-level dependent imaging (BOLD) responses in
healthy adults. They found drug-placebo differences using a
0.01 mg/kg intravenous dose of lorazepam (Cohen’s
d = 1.15). To achieve 80% power to detect an effect of this
size, a sample of 21 subjects per group would be required.
We are therefore recruiting 25 younger adults and 25
older adults for this study in order to compensate for pos-
sible attrition.
Lorazepam dosage
We conducted an unpublished pilot study in order to de-
termine the largest lorazepam dosage that would not
cause sedation. We used 2mg of lorazepam as the highest
dosage because previous studies using lorazepam with an
fMRI design have used oral doses of 2mg [32, 33]. We
assessed drowsiness using a visual analog scale and psy-
chomotor vigilance task in healthy adults at doses of 0.5
mg, 1mg, and 2mg of lorazepam.
The visual analog scale entailed participants rating
their current state on a continuum for the following
states: anxious, happy, drowsy, fearful, sad, and excited.
The psychomotor vigilance task was a 5-min sustained
attention reaction time task. Participants completed both
tasks at five, 20-min intervals over the course of two
hours [32, 33], with the first testing trial taking place im-
mediately after drug administration.
Both the 1 mg and 2mg dosages produced significant
sedation by these measures whereas the 0.5 mg dosage
typically did not. Thus, we decided to use a 0.5 mg dos-
age of lorazepam.
Session design
After completing a telephone screening process and eli-
gibility is confirmed, subjects participate in two separate
fMRI sessions. In one of the fMRI sessions, participants
are given a placebo pill approximately 1 h before the
scanning session. In the other fMRI session, a 0.5 mg
oral dose of lorazepam is administered approximately 1
h before the session. Participants provide verbal consent
during the screening interview and written consent at
the beginning of Session 1. See Table 5 for an overview
of the session flow for the drug study.
Each fMRI session lasts approximately 45 min and in-
cludes four different tasks to elicit activation in the vis-
ual, auditory, and somatosensory cortices. These fMRI
sessions follow the exact same protocol described for the
main study. In addition, participants complete a visual
analog scale and psychomotor vigilance task just before
and immediately following the fMRI scans to assess po-
tential drowsiness.
Participants are randomly assigned to one of four ses-
sion orders as depicted in Table 6. Participants are
assigned to their condition after they are deemed eligible
to participate in the study and before their sessions are
Table 4 Drug study exclusion and inclusion criteria
Exclusion Criteria Inclusion Criteria
• Glaucoma
• Respiratory problems
• Benzodiazepine allergy
• Past or present
chemotherapy
• Immune system disorder
• Kidney or liver disease
• Hearing problems or use of a
hearing aid
• Color blindness
• Motor control problems
• Psychotropic medication
• Current depression or
anxiety, or occurrence of
depression/anxiety within 5
years
• Concussion with
unconsciousness for 5 min or
more
• Pregnancy or attempting to
become pregnant
• More than 4 alcoholic drinks
per week for women, more
than 6 for men
• History of drug or alcohol
abuse or addiction
• Weight greater than 250
pounds
• MRI incompatibility
(claustrophobic, foreign metallic
objects, pacemaker, etc.)
• Age 18–29 years or 65 years and older
• Right-handed
• Native English speaker
• Healthy (i.e., no debilitating conditions,
mental illness, or head trauma)
Table 5 Overview of experimental flow for the drug study.
Conditions and task orders are further outlined in Table 6
Drug Study
Timepoint: Enrolment Session 1 Session 2
Enrolment:
Eligibility screen X
Informed consent X X
Condition Allocation X
Intervention:
Groups 1A & 1B Placebo X
Groups 1A & 1B Lorazepam X
Groups 2A & 2B Placebo X
Groups 2A & 2B Lorazepam X
MRI:
Groups 1A & 2A fMRI Tasks
(visual-motor)
X
Groups 1A & 2A fMRI Tasks
(motor-visual)
X
Groups 1B & 2B fMRI Tasks
(visual-motor)
X
Groups 1B & 2B fMRI Tasks
(motor-visual)
X
All Groups fMRI Resting State X X
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scheduled. We assign conditions by rotating through
them in a sequential order: 1A, 1B, 2A, 2B. This method
ensures that we have an equal number of participants in
each condition. Because the conditions are assigned be-
fore the participants’ sessions are scheduled, the condi-
tions are not necessarily conducted in sequential order
across participants. The session orders are used to coun-
terbalance the lorazepam administration and the presen-
tation of the motor and visual fMRI tasks. Half of the
participants receive the placebo during their first session
and lorazepam during their second session; the other half
receive the lorazepam during the first session and placebo
during the second session. The method of counterbalan-
cing the fMRI tasks is the same as in the main study.
Participants are not told which pill they receive on
which day – they are blinded to the drug administration
order. However, the experimenter conducting the study
session is not blind to the drug administration, because
a single experimenter oversees assigning participant con-
ditions, handling prescription requests, and conducting
the study sessions.
fMRI session protocol
Image acquisition parameters for the fMRI session are
the same as in the main study. Subjects participate in
two fMRI sessions on separate days: one with placebo
and one with lorazepam.
Preprocessing and analysis pipelines
Magnetic resonance imaging
Anatomical MRI
We use surface-based methods as implemented in Free-
Surfer to construct a cortical surface for each participant
from their high-resolution T1-weighted anatomical image.
Functional MRI
Task-based fMRI data preprocessing FreeSurfer and
FSFAST are used to perform the preprocessing and
first-level analyses of the fMRI data [34]. Preprocessing
procedures include motion correction, and spatial
smoothing using a Gaussian kernel with full width half
maximum (FWHM) of 5mm.
Multi-voxel pattern analysis (MVPA) Neural distinct-
iveness is assessed using MVPA in functionally defined
regions of interest (ROIs). Neural responses are first esti-
mated using a GLM implemented in FSFAST. For each
task, responses to the two experimental conditions (vis-
ual task: faces and houses; auditory task: speech and
music; motor task: left and right finger tapping; tactile
task: left and right vibrotactile stimulation) are modelled
using a block design, with models including separate re-
gressors for each of the experimental blocks convolved
with a canonical hemodynamic response function.
Using FreeSurfer’s Cortical Parcellation technique, four
bilateral anatomical masks, one for each task are created
for each participant using their T1-weighted structural
image. Parcellation results are reviewed and, if necessary,
manually corrected. For the visual task, this mask in-
cludes the fusiform gyrus and the parahippocampal
gyrus. For the auditory task, it includes superior tem-
poral gyrus, transverse temporal gyrus, bank of the su-
perior temporal sulcus, and supramarginal gyrus. And
for the motor and tactile tasks this mask includes the
precentral gyrus, postcentral gyrus and supramarginal
gyrus. Next, in-house MATLAB code is used to combine
information from the anatomical masks and the task
GLMs to create a functional ROI for each task and par-
ticipant. First, vertices within each participant’s anatom-
ical mask are sorted based on activation level for one of
the experimental conditions vs. rest. Then, a second list
is created by sorting vertices within the anatomical ROI
based on their activation level for the other experimental
condition vs. rest. Finally, the functional ROI is defined
by alternating between the two sorted lists, adding the
most active voxel (that has not already been included)
for the first experimental condition, then adding the
most active voxel that has not already been included for
the other condition, and so on. This procedure con-
tinues until the target functional ROI size is reached.
This approach was chosen in order to include voxels ac-
tivated by both conditions, without biasing the ROI to
have more voxels associated with either condition.
Next, the activation estimates within each participant’s
functional ROI are used to measure the distinctiveness
of multi-voxel representations for conditions of interest
in each experimental task. Inspired by Haxby and col-
leagues [35], we compute Pearson correlations to esti-
mate how similar activation patterns to the same
stimulus type are within the functional ROI (e.g., how
similar are activation patterns evoked by different face
blocks? How similar are activation patterns evoked by
different house blocks?). We then average all of the
within-condition correlations to get an estimate of with-
in-condition reliability. We also compute correlations be-
tween activation patterns evoked by different conditions (e.g.,
how similar is a face-evoked pattern to a house-evoked
Table 6 Drug pilot session orders
Group Session 1 Session 2
1A Placebo fMRI
fMRI task order: visual-motor
Lorazepam fMRI
fMRI task order: motor-visual
1B Placebo fMRI
fMRI task order: motor-visual
Lorazepam fMRI
fMRI task order: visual-motor
2A Lorazepam fMRI
fMRI task order: visual-motor
Placebo fMRI
fMRI task order: motor-visual
2B Lorazepam fMRI
fMRI task order: motor-visual
Placebo fMRI
fMRI task order: visual-motor
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pattern?) and average all of the between-condition correla-
tions to get an estimate of between-condition similarity. Fi-
nally, we define neural distinctiveness as the difference
between the average within-condition correlation and the
average between-condition correlation. This neural distinct-
iveness measure is the difference between two correlations
and can therefore range from − 2 (very low neural distinct-
iveness, indicating that between-condition correlations are
actually higher than within-condition correlations) to + 2
(very high neural distinctiveness, indicating that within-con-
dition correlations are much higher than between-condition
correlations). This approach is used rather than alternative
classification methods (i.e., support vector machines) that
only produce a few distinct accuracy values and that are
prone to ceiling effects. Neural distinctiveness is measured
separately for each task and each participant. To assess dif-
ferences in neural distinctiveness between young and older
participants, neural distinctiveness values from the visual,
auditory, motor and tactile tasks will each be entered into
separate ANOVAs comparing the young and older partici-
pant groups.
Resting-state fMRI data preprocessing Preprocessing
of the resting-state fMRI data is performed using SPM12
[36]. Preprocessing steps include slice-time correction, re-
alignment, segmentation of structural images, normalization
into standard MNI space, and spatial smoothing. The
Artifact Detection Toolbox (ART) [37] is used to account
for head motion in the scanner. An image is flagged as an
outlier if 1) head displacement in the x, y, or z direction is
greater than 0.5mm from the previous frame; 2) the rota-
tional displacement is greater than .02 rad from the previous
frame; or 3) the global mean intensity of an image is greater
than 3 standard deviations from the mean image intensity of
the entire scan. Outliers are included as nuisance covariates
in the first-level GLM.
Additional denoising on the resting-state data is per-
formed using the SPM compatible CONN toolbox [38].
Data are first filtered using a temporal band-pass filter
of .008 to .09 Hz to ensure analyses focus on the
frequency band of interest and higher frequency sources
of noise are excluded. For additional noise reduction, the
anatomical component-based correction method,
aCompCor, is used. This method models the influence
of noise as a voxel-specific linear combination of mul-
tiple empirically estimated noise sources by producing
principal components from noise ROIs and subsequently
including them as nuisance parameters in the first level
GLM. To do this, each participant’s structural image is
segmented into white matter (WM), grey matter (GM),
and cerebrospinal fluid masks (CSF). Next, the WM and
CSF masks are eroded by one voxel to minimize partial
voluming with GM. These eroded WM and CSF masks
are thereafter used as noise ROIs.
The signals from all ROIs are extracted from the un-
smoothed functional images to avoid potential “spillage”
of the BOLD signal from nearby regions. Residual head
motion parameters (three rotations, three translations
and six parameters representing their first-order tem-
poral derivatives) and signals from WM and CSF are
regressed out during the calculation of functional con-
nectivity maps. Following preprocessing, we use graph
theoretical approaches to quantify network properties of
the brain during the resting state. Age differences in
these properties will then be explored using ANOVAs,
comparing young and older participants.
Magnetic Resonance Spectroscopy
Preprocessing and analysis
For each of the six MRS voxels collected, GABA concen-
trations are quantified using the MEGA-PRESS differ-
ence spectra using Gannet 3.0 [39], which is specifically
targeted for GABA edited MRS. Time domain data are
frequency- and phase- corrected using spectral registra-
tion and filtered with a 3-Hz exponential line broaden-
ing and zero-filled by a factor of 16. Gannet models the
GABA peak using a five-parameter Gaussian model be-
tween 2.19 and 3.55 pm, and the water peak using a
Gaussian-Lorentzian function. In all analyses, metabolite
concentration values are scaled to water, and expressed
in institutional units (IU). GABA estimates are then cor-
rected for the fraction of the voxel that is cerebrospinal
fluid (CSF) and white matter (WM) as opposed to grey
matter (GM) (using SPM12 segmentation), and for the
different water relaxation times in CSF, WM, and GM as
described in Harris et al. [40]. Age differences in GABA
concentrations will be explored via ANOVAs comparing
young and older participant groups.
Diffusion Weighted Images
Preprocessing
Diffusion-weighted imaged (DWI) are preprocessed using
MRtrix [41]. Preprocessing includes Echo-planar imaging
(EPI) correction, motion correction, and bias field correc-
tion. DWIs are intensity normalized across subjects based
on the median b = 0 s/mm2 intensity within a white matter
mask [42]. Images are up-sampled to an isotropic voxel size
of 1.3mm using b-spline interpolation [42]. Fiber orienta-
tion distributions (FODs) are computed using robust con-
strained spherical deconvolution (rCSD) [43]. A group
average response is used to estimate FODs in all subjects,
as described in Raffelt et al. [42]. Registration is performed
using FODs at Imax = 4, 100 equally distributed apodised
point spread functions during FOD reorientation, with dis-
placement field smoothing (Gaussian kernel σ2 = 1), velocity
field smoothing (Gaussian kernel σ2 = 3), and an initial gra-
dient step of 0.2. A white matter template analysis fixel
mask was generated with an fmls peak value of 0.15. Whole
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brain probabilistic tractography is then performed on the
FOD template generating 20 million streamlines and SIFT
is applied with an output of 2 million streamlines.
Fixel-based analysis
We are performing fixel based analyses (FBA) of fiber
density (FD), fiber bundle cross-section (FC), and fiber
density and cross section (FDC). Measures of FD, FC
and FDC are computed as described in Raffelt et al. [44].
For the FC and FDC analyses, we include intra-cranial
volume (computed from T1-weighted images, using
FreeSurfer) as a nuisance covariate. Statistical analyses
are performed using the Connectivity-based Fixel En-
hancement (CFE) method, which gives a permutation
derived, multiple comparisons corrected p-value for each
fixel in the brain. We are performing CFE using 2 mil-
lion streamlines and default parameters (smoothing = 10
mm FWHM, C = 0.5, E = 2, H = 3; taken from Raffelt et
al. [45]). In this analysis, C is a constant weighting how
structurally connected fixels (hypothesized to share
underlying axons) contribute to the enhancement of other
fixels. The H parameter allows increasing weight to an ex-
tent (i.e., a group of connected fixels) at higher test-statistic
thresholds, and E influences how much the extent influ-
ences the enhancement as it scales in size. For further de-
tails of these parameters, see Raffelt et al. [45].
Discussion
Tens of millions of otherwise healthy people are already
experiencing age-related behavioral impairments, and
based on population projections, that number is going
to grow significantly in the coming years. However, there
are substantial individual differences in the degree of
cognitive decline that people experience as they age. We
hypothesize that age-related declines in neural distinct-
iveness (neural dedifferentiation) play a role in the be-
havioral impairments associated with age. The Michigan
Neural Distinctiveness (MiND) project investigates the
scope of neural dedifferentiation, whether age-related re-
ductions in GABA may be a contributing cause, and the
behavioral consequences of neural dedifferentiation. De-
veloping an understanding of the source of individual
differences in aging is an important step in designing in-
terventions that could slow, or conceivably even reverse,
the behavioral impairments associated with healthy aging.
This study is innovative in at least four ways. First, we are
collecting fMRI, MRS, and behavioral measures in the same
subjects, a rare combination. Doing so will allow us to dir-
ectly investigate the relationship between neural distinctive-
ness (assessed using fMRI), GABA levels (assessed using
MRS), and age-related behavioral declines (assessed using
psychophysical and assessment techniques).
Second, we are using multivariate pattern analysis
(MVPA) techniques that allow us to study neural
activation patterns rather than treating every brain voxel
as independent (as more traditional univariate tech-
niques do). Multivoxel analyses often reveal information
that univariate analyses miss [46, 47].
Third, we are explicitly investigating individual differences
in neurochemistry, neural representation, and behavioral per-
formance. A lot of work on the neuroscience of aging investi-
gates group differences between young and older subjects
and ignores individual differences between subjects in the
same age group. However, some older subjects experience
significantly greater behavioral declines than others, and
these individual differences could provide important insights
into the underlying causes of age-related behavioral declines.
Finally, the proposed research offers the potential to
inspire a new approach to therapy for age-related behav-
ioral impairments. The majority of current interventions
focus on behavioral training (either cognitive training or
physical exercise) [48–51]. However, if we can demon-
strate that reductions in GABA levels play an important
role, then biological interventions (e.g., GABA agonists
and related pharmaceuticals) might also be a fruitful
therapeutic path to pursue.
This study does have limitations. One limitation is that
the drug study is single blinded rather than double
blinded (the participants are blinded, but the experi-
menter is not). The main concern with not having an ex-
perimenter blind to the drug administration is the
potential for biasing outcomes. However, the outcome of
interest in the drug study is the degree of neural
distinctiveness observed using fMRI over which partici-
pants presumably do not have conscious control. Fur-
thermore, the experimenter has almost no interaction
with participants during the fMRI session so there is
very little opportunity for the experimenter’s knowledge
of the drug administration to influence the participant.
Finally, the experimenter adheres to a script during the
session that is identical regardless of placebo or Loraze-
pam administration.
Another limitation is that the study is cross-sectional
and not longitudinal. A longitudinal study would be
ideal in studying age-related changes in cognition, be-
havior, and neural chemistry because we could observe
how these changes occur over time in each individual
participant. However, a longitudinal study investigating
changes from young adulthood to older adulthood
would require a span of roughly 40 to 50 years, which is
not feasible for the current project.
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